(Reuters) – The U.S. Food and Drug Administration added a new black-box warning, its harshest, to the label of Pfizer Inc’s arthritis drug, Xeljanz, citing increased risk of major cardiac-related problems in some patients, the drugmaker said on Friday.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Anil D’Silva)
